Filing Flows › Comparisons › REGN vs TEVA
Regeneron Pharmaceuticals vs Teva Pharmaceutical Industries: REGN and TEVA compared
Regeneron Pharmaceuticals is the larger company: $5.1B of revenue in its latest quarter (Q3 2026) against $4.4B for Teva Pharmaceutical Industries (Q3 2026). Regeneron Pharmaceuticals is growing faster (+36% against -2% a year earlier). Regeneron Pharmaceuticals is more profitable, with an operating margin of 40.0% against 16.2%.
Where the money goes: REGN and TEVA
Regeneron Pharmaceuticals (REGN) · Q3 2026
Regeneron Pharmaceuticals, Q3 2026: revenue $5.1B (+36% year over year), operating margin 40.0%, net earnings $1.9B, operating cash flow $1.8B. The chart follows the revenue to costs, profit and cash.
Teva Pharmaceutical Industries (TEVA) · Q3 2026
Teva Pharmaceutical Industries, Q3 2026: revenue $4.4B (-2% year over year), operating margin 16.2%, net earnings $234M, operating cash flow $241M. The chart follows the revenue to costs, profit and cash.
| Regeneron Pharmaceuticals (REGN) | Teva Pharmaceutical Industries (TEVA) | |
|---|---|---|
| Latest quarter | Q3 2026 | Q3 2026 |
| Revenue | $5.1B | $4.4B |
| Revenue growth, Y/Y | +36% | -2% |
| Gross margin | — | 55.5% |
| Operating margin | 40.0% | 16.2% |
| Net earnings | $1.9B | $234M |
| Net margin | 38.1% | 5.3% |
| Operating cash flow | $1.8B | $241M |
| Free cash flow | $1.5B | $121M |
| Market value | $95.3B | $49.4B |
| P/E | 20.0× | 95.0× |
| Analysts’ mean target | $977.93 | $49.08 |
Where the revenue comes from
Regeneron Pharmaceuticals
- Collaboration revenue: $3.0B (59%)
- Net product sales: $1.8B (35%)
- Other revenue: $310M (6%)
- Lynozyfic: $19.0M (0%)
Teva Pharmaceutical Industries
- Sale of goods: $3.7B (85%)
- Distribution: $421M (10%)
- Other: $184M (4%)
- Licensing arrangements: $49.0M (1%)
Questions
Which is bigger, Regeneron Pharmaceuticals or Teva Pharmaceutical Industries?
Regeneron Pharmaceuticals is the larger company: $5.1B of revenue in its latest quarter (Q3 2026) against $4.4B for Teva Pharmaceutical Industries (Q3 2026).
Is Regeneron Pharmaceuticals or Teva Pharmaceutical Industries growing faster?
Regeneron Pharmaceuticals is growing faster (+36% against -2% a year earlier).
Which is more profitable, Regeneron Pharmaceuticals or Teva Pharmaceutical Industries?
Regeneron Pharmaceuticals is more profitable, with an operating margin of 40.0% against 16.2%.
More: Regeneron Pharmaceuticals earnings · how Regeneron Pharmaceuticals makes money · Teva Pharmaceutical Industries earnings · how Teva Pharmaceutical Industries makes money
From the companies' latest 10-Q, 10-K or earnings release (10-Q filed Oct 30, 2026; 10-Q filed Nov 3, 2026). Fiscal quarters can end on different dates. Not investment advice.